More recently, melanoma-derived EVs isolated from plasma of melanoma patients using CSPG4-binding antibodies were shown to activate NF-κB in autologous, peripheral CD8+ T cells, while pharmacological NF-κB inhibition could reverse EV-mediated suppression of T cell proliferation (15). This evidence concerns the gene NFKB1 and melanoma.